Since we observed a good reliability of IHC staining in grades 2 and 3 gliomas, here we sought to thoroughly characterize HMGB2 expression in validation cohort 2, a large cohort of grade 4 astrocytomas originally diagnosed as GBMs and arranged in 12 TMAs (Table 2). This evidence concerns the gene HMGB2 and central nervous system cancer.